Saheed Ekundayo Sanyaolu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saheed Ekundayo Sanyaolu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Omobolanle I. Ogundele
Faculty of Pharmacy, Olabisi Onabanjo University
3 shared publicationsAyomide O. Okundare
Department of Biomedical Engineering, Ulster University
2 shared publicationsDiana O. Wilson
Department of Clinical Pharmacy, Niger Delta University
2 shared publicationsFadilulahi A. Usman
Department of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research
2 shared publications- Godspower Onavbavba
National Institute for Pharmaceutical Research and Development Abuja Federal Capital Territory Nigeria
2 shared publications Habeebat O. Oludaisi
Faculty of Pharmacy, Olabisi Onabanjo University
2 shared publications
Latest Publications
- Open Access
- 11 April 2026
- Published by Premier Science in Premier Journal of Biomedical Science
Stem Cell-Based Repair and Regeneration of Cardiovascular Tissues: A Narrative Review
Cardiovascular diseases remain the leading cause of global morbidity and mortality, with the limited intrinsic regenerative capacity of the adult heart contributing to poor outcomes. Stem cell therapy represents a promising strategy to restore myocardial function; however, the evidence base is fragmented, with limited comprehensive synthesis on the applications of stem cells in human cardiovascular regeneration. This review aimed to assess current evidence on stem cell applications for cardiovascular repair and regeneration. A search of PubMed, Web of Science, and the Cochrane Library was performed, supplemented by Google Scholar, to identify clinical studies published between January 1, 2020 and December 31, 2025. Data extraction focused on study design, patient demographics, interventions, delivery methods, and outcomes. Findings were synthesized narratively. A total of 27 clinical studies, reporting findings on diverse stem cell populations, were included. Stem cells used in cardiac regenerative therapy include mesenchymal stromal cells, bone marrow-derived mesenchymal stromal cells, mesenchymal precursor cells, adipose-derived stem cells, stem/progenitor cells, umbilical cord blood-derived mononuclear cells, cardiosphere-derived cells, cardiopoietic stem cells, human-induced pluripotent stem cell-derived cardiomyocytes, and multilineage-differentiating stress-enduring cells. Findings demonstrate that stem cell therapies are safe and feasible, with improvements observed in surrogate endpoints. However, long‑term follow‑up often reveals attenuation of early benefits. Advancements in therapy include delivery methods, with hydrogel encapsulation, engineered grafts, and patch‑based implantation showing promise in enhancing cell survival and retention. Paracrine‑focused approaches, including extracellular vesicle-enhanced therapy and secretome administration, show promising advancements, and novel cell types such as Muse cells, mesenchymal progenitor cells, and cardiosphere-derived cells represent frontiers in regenerative cardiology. Current evidence supports the promise of stem cells for cardiovascular repair and regeneration, though robust long-term clinical outcomes remain to be established.
- 11 April 2026
- Published by Premier Science in Premier Journal of Biomedical Science
Open AccessStem Cell-Based Repair and Regeneration of Cardiovascular Tissues: A Narrative Review
Cardiovascular diseases remain the leading cause of global morbidity and mortality, with the limited intrinsic regenerative capacity of the adult heart contributing to poor outcomes. Stem cell therapy represents a promising strategy to restore myocardial function; however, the evidence base is fragmented, with limited comprehensive synthesis on the applications of stem cells in human cardiovascular regeneration. This review aimed to assess current evidence on stem cell applications for cardiovascular repair and regeneration. A search of PubMed, Web of Science, and the Cochrane Library was performed, supplemented by Google Scholar, to identify clinical studies published between January 1, 2020 and December 31, 2025. Data extraction focused on study design, patient demographics, interventions, delivery methods, and outcomes. Findings were synthesized narratively. A total of 27 clinical studies, reporting findings on diverse stem cell populations, were included. Stem cells used in cardiac regenerative therapy include mesenchymal stromal cells, bone marrow-derived mesenchymal stromal cells, mesenchymal precursor cells, adipose-derived stem cells, stem/progenitor cells, umbilical cord blood-derived mononuclear cells, cardiosphere-derived cells, cardiopoietic stem cells, human-induced pluripotent stem cell-derived cardiomyocytes, and multilineage-differentiating stress-enduring cells. Findings demonstrate that stem cell therapies are safe and feasible, with improvements observed in surrogate endpoints. However, long‑term follow‑up often reveals attenuation of early benefits. Advancements in therapy include delivery methods, with hydrogel encapsulation, engineered grafts, and patch‑based implantation showing promise in enhancing cell survival and retention. Paracrine‑focused approaches, including extracellular vesicle-enhanced therapy and secretome administration, show promising advancements, and novel cell types such as Muse cells, mesenchymal progenitor cells, and cardiosphere-derived cells represent frontiers in regenerative cardiology. Current evidence supports the promise of stem cells for cardiovascular repair and regeneration, though robust long-term clinical outcomes remain to be established.
- Open Access
- 15 December 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 6 (1)
Rhythm Control and Risk Reduction: Evidence From a Narrative Review on Therapeutic Advances in Cardiac Arrhythmia Management
With the growing prevalence of cardiac arrhythmias, effective management is crucial to improve quality of life, reduce the risk of complications, and enhance survival rates. This narrative review aimed to comprehensively provide updates regarding the clinical management of cardiac arrhythmias. Lifestyle modifications, pharmacological interventions, and procedural therapies were identified to enhance cardiac rhythm and rate control, as well as address underlying comorbid factors. Lifestyle modalities included maintaining a healthy weight, ensuring an appropriate diet, exercising regularly, managing stress, and avoiding triggers like alcohol. However, uncertainty still persists regarding the harms or benefits of these foods rich in chocolate and caffeine. While lifestyle interventions are foundational, their effectiveness depends on disease severity and individualized treatment goals. Tailored strategies, including vagal maneuvers and genetics-guided therapy, offer promise for arrhythmia management. Recent advancements in therapies have also been uncovered, including the exploration of intranasal etripamil, inhaled flecainide, and cognitive behavioral therapy, which demonstrate potential for improved disease management. Minimally invasive technologies, including wearable monitors, robotic-assisted platforms, renal denervation, and procedures like the Maze technique and cardioneuroablation, are also being explored for reshaping arrhythmia treatment and recovery timelines. These innovations reinforce a personalized and data-driven framework for cardiovascular care and underscore the importance of integrating precision-based strategies to reduce arrhythmia burden, enhance treatment efficacy, and guide future research into safer and more targeted therapies.
- 15 December 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 6 (1)
Open AccessRhythm Control and Risk Reduction: Evidence From a Narrative Review on Therapeutic Advances in Cardiac Arrhythmia Management
With the growing prevalence of cardiac arrhythmias, effective management is crucial to improve quality of life, reduce the risk of complications, and enhance survival rates. This narrative review aimed to comprehensively provide updates regarding the clinical management of cardiac arrhythmias. Lifestyle modifications, pharmacological interventions, and procedural therapies were identified to enhance cardiac rhythm and rate control, as well as address underlying comorbid factors. Lifestyle modalities included maintaining a healthy weight, ensuring an appropriate diet, exercising regularly, managing stress, and avoiding triggers like alcohol. However, uncertainty still persists regarding the harms or benefits of these foods rich in chocolate and caffeine. While lifestyle interventions are foundational, their effectiveness depends on disease severity and individualized treatment goals. Tailored strategies, including vagal maneuvers and genetics-guided therapy, offer promise for arrhythmia management. Recent advancements in therapies have also been uncovered, including the exploration of intranasal etripamil, inhaled flecainide, and cognitive behavioral therapy, which demonstrate potential for improved disease management. Minimally invasive technologies, including wearable monitors, robotic-assisted platforms, renal denervation, and procedures like the Maze technique and cardioneuroablation, are also being explored for reshaping arrhythmia treatment and recovery timelines. These innovations reinforce a personalized and data-driven framework for cardiovascular care and underscore the importance of integrating precision-based strategies to reduce arrhythmia burden, enhance treatment efficacy, and guide future research into safer and more targeted therapies.
- Open Access
- 14 November 2025
- Published by Premier Science in Premier Journal of Science
- Vol. 14 (1)
Updates on the Clinical Management of Hypertension: A Narrative Review
Hypertension is a common risk factor for various cardiovascular diseases, highlighting the need for ongoing evaluation of current pharmacotherapies and patient management strategies. This narrative review addresses these gaps, emphasizing a multifaceted approach to care that integrates cardiovascular monitoring, lifestyle modification, pharmacologic therapy, and procedural therapies. A search was conducted in PubMed, Scopus, and the Cochrane Library for studies published between 1st January 2010 and 30th June 2025 on the clinical management of hypertension. Search terms combined keywords using Boolean operators to optimize sensitivity and specificity. The search revealed 26 primary articles with recent findings on the management of hypertension. While lifestyle interventions are encouraged, their effectiveness depends on disease severity and individualized treatment goals. Combination antihypertensive therapy has shown greater efficacy and tolerability than monotherapy. Newer therapies, including zilebesiran, lorundrostat, riociguat, M-atrial natriuretic peptide, and aprocitentan, produce modest blood pressure reductions that are associated with lower cardiovascular risk. Minimally invasive procedural therapeutics, including renal denervation, baroreflex activation therapy, and wearable monitors, have also been reported to hold promise for addressing resistant hypertension. These innovations may address the limitations of conventional therapies and reinforce the importance of a personalized and data-driven framework for cardiovascular care. The findings can potentially guide health practitioners, researchers, and policymakers on improving hypertension care and outcomes while also enhancing precision-based therapies for the diverse patient population.
- 14 November 2025
- Published by Premier Science in Premier Journal of Science
- Vol. 14 (1)
Open AccessUpdates on the Clinical Management of Hypertension: A Narrative Review
Hypertension is a common risk factor for various cardiovascular diseases, highlighting the need for ongoing evaluation of current pharmacotherapies and patient management strategies. This narrative review addresses these gaps, emphasizing a multifaceted approach to care that integrates cardiovascular monitoring, lifestyle modification, pharmacologic therapy, and procedural therapies. A search was conducted in PubMed, Scopus, and the Cochrane Library for studies published between 1st January 2010 and 30th June 2025 on the clinical management of hypertension. Search terms combined keywords using Boolean operators to optimize sensitivity and specificity. The search revealed 26 primary articles with recent findings on the management of hypertension. While lifestyle interventions are encouraged, their effectiveness depends on disease severity and individualized treatment goals. Combination antihypertensive therapy has shown greater efficacy and tolerability than monotherapy. Newer therapies, including zilebesiran, lorundrostat, riociguat, M-atrial natriuretic peptide, and aprocitentan, produce modest blood pressure reductions that are associated with lower cardiovascular risk. Minimally invasive procedural therapeutics, including renal denervation, baroreflex activation therapy, and wearable monitors, have also been reported to hold promise for addressing resistant hypertension. These innovations may address the limitations of conventional therapies and reinforce the importance of a personalized and data-driven framework for cardiovascular care. The findings can potentially guide health practitioners, researchers, and policymakers on improving hypertension care and outcomes while also enhancing precision-based therapies for the diverse patient population.
- Open Access
- 30 July 2025
- Published by Premier Science in Premier Journal of Biomedical Science
- Vol. 4 (1)
Impact of SGLT2 Inhibitors in the Management of Diabetes and Heart Failure Comorbidity: A Review of Current Evidence
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a novel class of medication for managing both type 2 diabetes mellitus and heart failure (HF), offering significant cardioprotective benefits beyond glycemic control. This study reviewed current findings on the efficacy of SGLT2 inhibitors as a therapeutic approach for managing diabetes and HF comorbidity. Based on reports from clinical trials on empagliflozin, dapagliflozin, canagliflozin, sotagliflozin, and ertugliflozin, the review revealed that SGLT2 inhibitors demonstrated superior efficacy compared to placebo for managing HF and reducing the risk of major adverse cardiovascular events in patients with and without diabetes mellitus. However, higher incidences of adverse effects such as diarrhea, amputation, hypoglycemia, genitourinary infections, and diabetic ketoacidosis were reported in patients who received SGLT2 inhibitors. Most of the trials represent the initial studies undertaken for each of the drugs, and their findings informed regulatory approvals for HF management and reduction of cardiovascular events. While most of the studies focused on assessing the clinical outcomes, a few mechanistic studies were undertaken, which revealed that the reported cardiovascular outcomes of SGLT2 inhibitors could be due to the promotion of reverse cardiac remodeling. Furthermore, only a few of the studies compared the clinical efficacy of SGLT2 inhibitors with that of other classes of hypoglycemic agents. This review highlighted research directions that can contribute to a more comprehensive understanding of SGLT2 inhibitor safety and efficacy, ensuring optimal utilization in diverse patient populations.
- 30 July 2025
- Published by Premier Science in Premier Journal of Biomedical Science
- Vol. 4 (1)
Open AccessImpact of SGLT2 Inhibitors in the Management of Diabetes and Heart Failure Comorbidity: A Review of Current Evidence
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a novel class of medication for managing both type 2 diabetes mellitus and heart failure (HF), offering significant cardioprotective benefits beyond glycemic control. This study reviewed current findings on the efficacy of SGLT2 inhibitors as a therapeutic approach for managing diabetes and HF comorbidity. Based on reports from clinical trials on empagliflozin, dapagliflozin, canagliflozin, sotagliflozin, and ertugliflozin, the review revealed that SGLT2 inhibitors demonstrated superior efficacy compared to placebo for managing HF and reducing the risk of major adverse cardiovascular events in patients with and without diabetes mellitus. However, higher incidences of adverse effects such as diarrhea, amputation, hypoglycemia, genitourinary infections, and diabetic ketoacidosis were reported in patients who received SGLT2 inhibitors. Most of the trials represent the initial studies undertaken for each of the drugs, and their findings informed regulatory approvals for HF management and reduction of cardiovascular events. While most of the studies focused on assessing the clinical outcomes, a few mechanistic studies were undertaken, which revealed that the reported cardiovascular outcomes of SGLT2 inhibitors could be due to the promotion of reverse cardiac remodeling. Furthermore, only a few of the studies compared the clinical efficacy of SGLT2 inhibitors with that of other classes of hypoglycemic agents. This review highlighted research directions that can contribute to a more comprehensive understanding of SGLT2 inhibitor safety and efficacy, ensuring optimal utilization in diverse patient populations.
- Open Access
- 26 July 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 4 (1)
Current Evidence on the Clinical Management of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review
Coronary artery disease (CAD) and acute coronary syndrome (ACS) share a pathophysiological basis of myocardial ischemia, primarily driven by atherosclerosis, plaque rupture, and thrombogenesis. Despite advancements in diagnosis and treatment, CAD and ACS continue to pose significant clinical challenges due to variable patient responses, limitations in pharmacological and interventional therapies, and gaps in long-term safety data. Current pharmacologic management integrates conventional agents such as aspirin, clopidogrel, anticoagulants, beta-blockers, and angiotensin-converting enzyme inhibitors. Furthermore, emerging therapies, such as proprotein convertase subtilisin kexin type 9 inhibitors, sodium-glucose co-transporter two inhibitors, RNA-based therapies, and anti-inflammatory agents such as canakinumab, offer innovative approaches to improving patient outcomes and addressing the limitations of traditional therapies. However, adherence remains a challenge, particularly in high-risk patients. Lifestyle modifications and interventional strategies, including percutaneous coronary intervention, coronary artery bypass grafting, transcatheter aortic valve replacement, and hybrid revascularization, provide tailored approaches based on disease severity. Mechanical circulatory support devices, such as Impella pumps, are also critical in managing cardiogenic shock. To optimize CAD and ACS management, a multidisciplinary approach that integrates pharmacological innovations, surgical expertise, algorithm-based interventions, and precision medicine is essential. Improving adherence strategies and refining individualized treatment regimens will be key to advancing cardiovascular care globally.
- 26 July 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 4 (1)
Open AccessCurrent Evidence on the Clinical Management of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review
Coronary artery disease (CAD) and acute coronary syndrome (ACS) share a pathophysiological basis of myocardial ischemia, primarily driven by atherosclerosis, plaque rupture, and thrombogenesis. Despite advancements in diagnosis and treatment, CAD and ACS continue to pose significant clinical challenges due to variable patient responses, limitations in pharmacological and interventional therapies, and gaps in long-term safety data. Current pharmacologic management integrates conventional agents such as aspirin, clopidogrel, anticoagulants, beta-blockers, and angiotensin-converting enzyme inhibitors. Furthermore, emerging therapies, such as proprotein convertase subtilisin kexin type 9 inhibitors, sodium-glucose co-transporter two inhibitors, RNA-based therapies, and anti-inflammatory agents such as canakinumab, offer innovative approaches to improving patient outcomes and addressing the limitations of traditional therapies. However, adherence remains a challenge, particularly in high-risk patients. Lifestyle modifications and interventional strategies, including percutaneous coronary intervention, coronary artery bypass grafting, transcatheter aortic valve replacement, and hybrid revascularization, provide tailored approaches based on disease severity. Mechanical circulatory support devices, such as Impella pumps, are also critical in managing cardiogenic shock. To optimize CAD and ACS management, a multidisciplinary approach that integrates pharmacological innovations, surgical expertise, algorithm-based interventions, and precision medicine is essential. Improving adherence strategies and refining individualized treatment regimens will be key to advancing cardiovascular care globally.
- Open Access
- 23 July 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 4 (1)
Radiomics-Based Diagnosis in Cardiology: Advances and Prospects
With the increasing need for faster and more accurate diagnosis in cardiology, radiomics presents an innovative approach for assessing medical images and diagnosing clinical conditions. This review aims to highlight the applications of radiomics in the diagnosis of cardiovascular conditions. The development of a radiomic model typically progresses as follows: image acquisition and preprocessing, image segmentation, image processing, feature extraction, feature selection, and machine learning modeling and validation. Image data is commonly obtained from cardiac computed tomography angiography, cardiac magnetic resonance imaging, echocardiography, and nuclear imaging. Using machine learning frameworks such as decision trees, random forests, support vector machines, XGBoost, and deep learning, radiomics-based models demonstrated better performance for diagnosis and prediction of cardiovascular events than models designed using conventional clinical risk factors. Radiomics is applied in plaque and adipose tissue characterization to determine the degree of stenosis or predict plaque rupture. In cardiomyopathies, radiomics is employed to distinguish between healthy and diseased tissues. A notable challenge hindering the integration of radiomics in clinical practice is the lack of standardization of study protocols, including image acquisition and processing. Multiple studies also highlighted the need for high-quality images as well as validation of the radiomics model using data from multiple data collection centers. Findings from this study revealed that, while notable advancements have been recorded in radiology-based diagnosis in cardiology, there is a need for further research effort to harmonize evidence and enable the real-world clinical application of radiomics.
- 23 July 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 4 (1)
Open AccessRadiomics-Based Diagnosis in Cardiology: Advances and Prospects
With the increasing need for faster and more accurate diagnosis in cardiology, radiomics presents an innovative approach for assessing medical images and diagnosing clinical conditions. This review aims to highlight the applications of radiomics in the diagnosis of cardiovascular conditions. The development of a radiomic model typically progresses as follows: image acquisition and preprocessing, image segmentation, image processing, feature extraction, feature selection, and machine learning modeling and validation. Image data is commonly obtained from cardiac computed tomography angiography, cardiac magnetic resonance imaging, echocardiography, and nuclear imaging. Using machine learning frameworks such as decision trees, random forests, support vector machines, XGBoost, and deep learning, radiomics-based models demonstrated better performance for diagnosis and prediction of cardiovascular events than models designed using conventional clinical risk factors. Radiomics is applied in plaque and adipose tissue characterization to determine the degree of stenosis or predict plaque rupture. In cardiomyopathies, radiomics is employed to distinguish between healthy and diseased tissues. A notable challenge hindering the integration of radiomics in clinical practice is the lack of standardization of study protocols, including image acquisition and processing. Multiple studies also highlighted the need for high-quality images as well as validation of the radiomics model using data from multiple data collection centers. Findings from this study revealed that, while notable advancements have been recorded in radiology-based diagnosis in cardiology, there is a need for further research effort to harmonize evidence and enable the real-world clinical application of radiomics.
- Open Access
- 14 June 2025
- Published by Premier Science in Premier Journal of Science
Outcomes of Clinical Trials on the Roles of Immune Checkpoint Inhibitors in the Management of Lung Cancers: A Comprehensive Review
Lung cancer is a deadly clinical condition that necessitates critical clinical intervention for its management. This comprehensive review summarizes findings from clinical trials that assessed the efficacy and safety of immune checkpoint inhibitors (ICIs) for the management of lung cancer. Scientific databases were explored for reports from clinical trials on ICI roles in lung cancer management. Small cell lung cancer mostly develops from chronic smoking, and it is refractory to treatment, resulting in complications and death. On the other hand, many treatment modalities are available for non-small-cell lung cancer, including surgery, radiotherapy, and systemic therapy. ICIs, classified into programmed death-1, programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 inhibitors, are used either alone or in combination with other targeted therapies or chemotherapy perioperatively to improve surgical outcomes for resectable lung cancer. Additionally, ICIs are also used in advanced unresectable metastatic lung cancer to reduce tumor growth or as palliative treatment to prolong survival and improve patients’ quality of life. ICI monotherapy, compared to placebo and platinum-based chemotherapy, elicited positive clinical outcomes in patients with lung cancer, resulting in longer overall survival and progression-free survival with tolerable side effect profiles. Similarly, combination therapy comprising ICIs alongside tyrosine kinase inhibitors, platinum-based chemotherapy, or radiotherapy resulted in superior efficacy compared to drug combinations without ICIs but with higher incidences of adverse events. Notably, higher tumor expression of PD-L1 improved clinical response to ICIs.
- 14 June 2025
- Published by Premier Science in Premier Journal of Science
Open AccessOutcomes of Clinical Trials on the Roles of Immune Checkpoint Inhibitors in the Management of Lung Cancers: A Comprehensive Review
Lung cancer is a deadly clinical condition that necessitates critical clinical intervention for its management. This comprehensive review summarizes findings from clinical trials that assessed the efficacy and safety of immune checkpoint inhibitors (ICIs) for the management of lung cancer. Scientific databases were explored for reports from clinical trials on ICI roles in lung cancer management. Small cell lung cancer mostly develops from chronic smoking, and it is refractory to treatment, resulting in complications and death. On the other hand, many treatment modalities are available for non-small-cell lung cancer, including surgery, radiotherapy, and systemic therapy. ICIs, classified into programmed death-1, programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 inhibitors, are used either alone or in combination with other targeted therapies or chemotherapy perioperatively to improve surgical outcomes for resectable lung cancer. Additionally, ICIs are also used in advanced unresectable metastatic lung cancer to reduce tumor growth or as palliative treatment to prolong survival and improve patients’ quality of life. ICI monotherapy, compared to placebo and platinum-based chemotherapy, elicited positive clinical outcomes in patients with lung cancer, resulting in longer overall survival and progression-free survival with tolerable side effect profiles. Similarly, combination therapy comprising ICIs alongside tyrosine kinase inhibitors, platinum-based chemotherapy, or radiotherapy resulted in superior efficacy compared to drug combinations without ICIs but with higher incidences of adverse events. Notably, higher tumor expression of PD-L1 improved clinical response to ICIs.
- Open Access
- 3 April 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 3 (1)
Recent Advancements in the Management of Heart Failure: A Review
Heart failure is associated with considerable morbidity and mortality, resulting in high healthcare expenditure worldwide. The last decade has witnessed several significant developments and advances in the management of heart failure. To ensure rapid access to a concise overview of existing evidence for clinical decision-making regarding heart failure management, this study aimed to review scientific publications on emerging treatment approaches for heart failure, particularly in the last 10 years. Scientific databases, including PubMed, Scopus, Web of Science, and Cochrane Library, were explored for research articles on the advances in the management of heart failure and its comorbidities. A narrative review approach was employed in this report. Heart failure has multiple etiologies; hence, a critical aspect of its management involves the identification and treatment of the cause, which may include structural defects in the heart or pathologies from other parts of the body. Notable criteria for the classification of heart failure or for risk stratification are classification with the degree of ejection fraction and the New York Heart Association classification of heart failure. Challenges of traditional treatment strategies comprised lack of precision, treatment failure, adverse treatment outcomes, and short survival. In recent years, new drugs have been tested and approved for heart failure management, and some of them are included in the treatment guidelines for heart failure. Furthermore, precision medicine through genome editing and artificial intelligence-based innovations have revolutionized the management of healthcare. However, there are emerging concerns regarding the affordability and accessibility of the new treatment strategies.
- 3 April 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 3 (1)
Open AccessRecent Advancements in the Management of Heart Failure: A Review
Heart failure is associated with considerable morbidity and mortality, resulting in high healthcare expenditure worldwide. The last decade has witnessed several significant developments and advances in the management of heart failure. To ensure rapid access to a concise overview of existing evidence for clinical decision-making regarding heart failure management, this study aimed to review scientific publications on emerging treatment approaches for heart failure, particularly in the last 10 years. Scientific databases, including PubMed, Scopus, Web of Science, and Cochrane Library, were explored for research articles on the advances in the management of heart failure and its comorbidities. A narrative review approach was employed in this report. Heart failure has multiple etiologies; hence, a critical aspect of its management involves the identification and treatment of the cause, which may include structural defects in the heart or pathologies from other parts of the body. Notable criteria for the classification of heart failure or for risk stratification are classification with the degree of ejection fraction and the New York Heart Association classification of heart failure. Challenges of traditional treatment strategies comprised lack of precision, treatment failure, adverse treatment outcomes, and short survival. In recent years, new drugs have been tested and approved for heart failure management, and some of them are included in the treatment guidelines for heart failure. Furthermore, precision medicine through genome editing and artificial intelligence-based innovations have revolutionized the management of healthcare. However, there are emerging concerns regarding the affordability and accessibility of the new treatment strategies.
- Open Access
- 28 March 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 2 (1)
Integration of Machine Learning in Imaging Analysis for Clinical Diagnosis of Cardiovascular Diseases
In recent years, artificial intelligence (AI) has emerged as an important technology revolutionizing the diagnosis and prognosis of cardiovascular diseases. In cardiology, machine learning models can reduce the cost and time-to-diagnosis, as well as increase diagnostic precision, consequently improving the quality of care for patients. Therefore, this review provided an overview of innovative models in cardiology-based image analysis for disease diagnosis. Recent reports on studies evaluating the performance of these models were reviewed. Common approaches to training AI models include supervised learning, semi-supervised learning, unsupervised learning, and various other approaches. Logistic regression, support vector machines, random forests, cluster analysis, and neural networks are examples of machine learning architectures used in modern times. AI is used in cardiac magnetic resonance imaging to detect artifacts and assess image quality, as well as to quantify blood flow faster and more accurately. Convoluted neural networks are utilized in echocardiography and electrocardiography to enhance the precision of visualizing cardiac structures and assessing cardiac functions, respectively. AI models in X-ray imaging are employed to identify structural anomalies in the heart and assess their severity. In response to the need for high-quality data while safeguarding patient privacy and confidentiality, specialized databases with comprehensive datasets have been established, such as the UK Biobank and the MIT-BIH Malignant Ventricular Arrhythmia Database. Prospects in machine learning-based screening in cardiology include digital heart winners in precision medicine, explainable AI, and radionics.
- 28 March 2025
- Published by Premier Science in Premier Journal of Cardiology
- Vol. 2 (1)
Open AccessIntegration of Machine Learning in Imaging Analysis for Clinical Diagnosis of Cardiovascular Diseases
In recent years, artificial intelligence (AI) has emerged as an important technology revolutionizing the diagnosis and prognosis of cardiovascular diseases. In cardiology, machine learning models can reduce the cost and time-to-diagnosis, as well as increase diagnostic precision, consequently improving the quality of care for patients. Therefore, this review provided an overview of innovative models in cardiology-based image analysis for disease diagnosis. Recent reports on studies evaluating the performance of these models were reviewed. Common approaches to training AI models include supervised learning, semi-supervised learning, unsupervised learning, and various other approaches. Logistic regression, support vector machines, random forests, cluster analysis, and neural networks are examples of machine learning architectures used in modern times. AI is used in cardiac magnetic resonance imaging to detect artifacts and assess image quality, as well as to quantify blood flow faster and more accurately. Convoluted neural networks are utilized in echocardiography and electrocardiography to enhance the precision of visualizing cardiac structures and assessing cardiac functions, respectively. AI models in X-ray imaging are employed to identify structural anomalies in the heart and assess their severity. In response to the need for high-quality data while safeguarding patient privacy and confidentiality, specialized databases with comprehensive datasets have been established, such as the UK Biobank and the MIT-BIH Malignant Ventricular Arrhythmia Database. Prospects in machine learning-based screening in cardiology include digital heart winners in precision medicine, explainable AI, and radionics.
- Open Access
- 10 October 2024
- Published by Wiley in Public Health Challenges
- Vol. 3 (4) , e70006
Current State and Challenges of Local Production of Vaccines in Nigeria
Background: Vaccination protects the population against infectious diseases and reduces their transmissibility. Potentials exist for local production of vaccines in Nigeria, as a means of addressing public health needs. However, challenges exist in certain critical aspects which limit development in this area. This study aimed at evaluating the challenges of local vaccines’ manufacturing in Nigeria from the perspectives of relevant stakeholders.Methods: This was a cross‐sectional study. A structured questionnaire was used for data collection. The data obtained from the study were analysed descriptively.Results: More than half of the study participants (55.5%) agreed that significant gaps exist with respect to access to vaccines in Nigeria. Only about one‐quarter of the respondents (25.8%) were of the view that relevant legislative frameworks exist to support government funding in the area of vaccine production. One‐third of the participants (32.3%) expressed confidence in the availability of trained human resources for vaccine production. Close to two‐thirds of the respondents (61.7%) expressed dissatisfaction regarding the current funding for vaccine research and development, and a similar proportion (65.2%) were of the opinion that a lack of local manufacturing capacity contributed to the sub‐optimal access to vaccines. Moreover, two‐thirds (62.3%) disagreed that Nigeria was prepared for future pandemics.Conclusion: Ill‐suited policies, sub‐optimal infrastructure, and inadequate research and development funding, are some factors which the study identified as contributory to the lack of access to vaccines in Nigeria. There is a need to improve incentives, infrastructural development and build human resource capacity for vaccine research and development to enhance local production in Nigeria.
- 10 October 2024
- Published by Wiley in Public Health Challenges
- Vol. 3 (4) , e70006
Open AccessCurrent State and Challenges of Local Production of Vaccines in Nigeria
Background: Vaccination protects the population against infectious diseases and reduces their transmissibility. Potentials exist for local production of vaccines in Nigeria, as a means of addressing public health needs. However, challenges exist in certain critical aspects which limit development in this area. This study aimed at evaluating the challenges of local vaccines’ manufacturing in Nigeria from the perspectives of relevant stakeholders.Methods: This was a cross‐sectional study. A structured questionnaire was used for data collection. The data obtained from the study were analysed descriptively.Results: More than half of the study participants (55.5%) agreed that significant gaps exist with respect to access to vaccines in Nigeria. Only about one‐quarter of the respondents (25.8%) were of the view that relevant legislative frameworks exist to support government funding in the area of vaccine production. One‐third of the participants (32.3%) expressed confidence in the availability of trained human resources for vaccine production. Close to two‐thirds of the respondents (61.7%) expressed dissatisfaction regarding the current funding for vaccine research and development, and a similar proportion (65.2%) were of the opinion that a lack of local manufacturing capacity contributed to the sub‐optimal access to vaccines. Moreover, two‐thirds (62.3%) disagreed that Nigeria was prepared for future pandemics.Conclusion: Ill‐suited policies, sub‐optimal infrastructure, and inadequate research and development funding, are some factors which the study identified as contributory to the lack of access to vaccines in Nigeria. There is a need to improve incentives, infrastructural development and build human resource capacity for vaccine research and development to enhance local production in Nigeria.